|
1
|
Pignon JP, Bourhis J, Domenge C and
Designé L: Chemotherapy added to locoregional treatment for head
and neck squamous-cell carcinoma: Three meta-analyses of updated
individual data. MACH-NC Collaborative Group. Meta-analysis of
chemotherapy on head and neck cancer. Lancet. 355:949–955. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bourhis J, Le Maître A, Baujat B, Audry H
and Pignon J; Meta-Analysis of Chemotherapy in Head, Neck Cancer
Collaborative Group, ; Meta-Analysis of Radiotherapy in Carcinoma
of Head, Neck Collaborative Group, ; Meta-Analysis of Chemotherapy
in Nasopharynx Carcinoma Collaborative Group, : Individual
patients' data meta-analyses in head and neck cancer. Curr Opin
Oncol. 19:188–194. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Browman GP, Hodson DI, Mackenzie RJ,
Bestic N and Zuraw L; Cancer Care Ontario Practice Guideline
Initiative Head and Neck Cancer Disease Site Group, : Choosing a
concomitant chemotherapy and radiotherapy regimen for squamous cell
head and neck cancer: A systematic review of the published
literature with subgroup analysis. Head Neck. 23:579–589. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Forastiere AA, Goepfert H, Maor M, Pajak
TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, et
al: Concurrent chemotherapy and radiotherapy for organ preservation
in advanced laryngeal cancer. N Engl J Med. 349:2091–2209. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Denis F, Garaud P, Bardet E, Alfonsi M,
Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J and Calais G:
Final results of the 94-01 french head and neck oncology and
radiotherapy group randomized trial comparing radiotherapy alone
with concomitant radiochemotherapy in advanced-stage oropharynx
carcinoma. J Clin Oncol. 22:69–76. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wendt TG, Grabenbauer GG, Rödel CM, Thiel
HJ, Aydin H, Rohloff R, Wustrow TP, Iro H, Popella C and Schalhorn
A: Simultaneous radiochemotherapy versus radiotherapy alone in
advanced head and neck cancer: A randomized multicenter study. J
Clin Oncol. 16:1318–1324. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nabell L and Spencer S: Docetaxel with
concurrent radiotherapy in head and neck cancer. Semin Oncol. 30 6
Suppl 18:S89–S93. 2003. View Article : Google Scholar
|
|
8
|
Fujii M, Tsukuda M, Satake B, Kubota A,
Kida A, Kohno N, Okami K and Inuyama Y; Japan Cooperative Head and
Neck Oncology Group (JCHNOG), : Phase I/II trial of weekly
docetaxel and concomitant radiotherapy for squamous cell carcinoma
of the head and neck. Int J Clin Oncol. 9:107–112. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Furusaka T, Matsuda A, Saito T, Katsura Y
and Ikeda M: Concurrent chemoradiation therapy with docetaxel (DOC)
for laryngeal preservation in T2N0M0 glottic squamous cell
carcinomas. Acta Otolaryngol. 133:99–112. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Calais G, Bardet E, Sire C, Alfonsi M,
Bourhis J, Rhein B, Tortochaux J, Man YT, Auvray H and Garaud P:
Radiotherapy with concomitant weekly docetaxel for stages III/IV
oropharynx carcinoma. Results of the 98-02 GORTEC phase II trial.
Int J Radiat Oncol Biol Phys. 58:161–166. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Holmgren A: Thioredoxin. Annu Rev Biochem.
54:237–271. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Miyazaki K, Noda N, Okada S, Hagiwara Y,
Miyata M, Sakurabayashi I, Yamaguchi N, Sugimura T, Terada M and
Wakasugi H: Elevated serum level of thioredoxin in patients with
hepatocellular carcinoma. Biotherapy. 11:277–288. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nakamura H, Bai J, Nishinaka Y, Ueda S,
Sasada T, Ohshio G, Imamura M, Takabayashi A, Yamaoka Y and Yodoi
J: Expression of thioredoxin and glutaredoxin, redox-regulating
proteins, in pancreatic cancer. Cancer Detect Prev. 24:53–60.
2000.PubMed/NCBI
|
|
14
|
Grogan TM, Fenoglio-Prieser C, Zeheb R,
Bellamy W, Frutiger Y, Vela E, Stemmerman G, Macdonald J, Richter
L, Gallegos A and Powis G: Thioredoxin, a putative oncogene
product, is overexpressed in gastric carcinoma and associated with
increased proliferation and increased cell survival. Hum Pathol.
31:475–481. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kakolyris S, Giatromanolaki A, Koukourakis
M, Powis G, Souglakos J, Sivridis E, Georgoulias V, Gatter KC and
Harris AL: Thioredoxin expression is associated with lymph node
status and prognosis in early operable non-small cell lung cancer.
Clin Cancer Res. 7:3087–3091. 2001.PubMed/NCBI
|
|
16
|
Raffel J, Bhattacharyya AK, Gallegos A,
Cui H, Einspahr JG, Alberts DS and Powis G: Increased expression of
thioredoxin-1 in human colorectal cancer is associated with
decreased patient survival. J Lab Clin Med. 142:46–51. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nishiyama A, Matsui M, Iwata S, Hirota K,
Masutani H, Nakamura H, Takagi Y, Sono H, Gon Y and Yodoi J:
Identification of thioredoxin-binding protein-2/vitamin D(3)
up-regulated protein 1 as a negative regulator of thioredoxin
function and expression. J Biol Chem. 274:21645–21650. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Junn E, Han SH, Im JY, Yang Y, Cho EW, Um
HD, Kim DK, Lee KW, Han PL, Rhee SG and Choi I: Vitamin D3
up-regulated protein 1 mediates oxidative stress via suppressing
the thioredoxin function. J Immunol. 164:6287–6295. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Han SH, Jeon JH, Ju HR, Jung U, Kim KY,
Yoo HS, Lee YH, Song KS, Hwang HM, Na YS, et al: VDUP1 upregulated
by TGF-beta1 and 1,25-dihydorxyvitamin D3 inhibits tumor cell
growth by blocking cell-cycle progression. Oncogene. 22:4035–4046.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sui L, Dong Y, Watanabe Y, Yamaguchi F,
Hatano N, Izumori K and Tokuda M: Growth inhibitory effect of
D-allose on human ovarian carcinoma cells in vitro. Anticancer Res.
25:2639–2644. 2005.PubMed/NCBI
|
|
21
|
Yamaguchi F, Takata M, Kamitori K, Nonaka
M, Dong Y, Sui L and Tokuda M: Rare sugar D-allose induces specific
up-regulation of TXNIP and subsequent G1 cell cycle arrest in
hepatocellular carcinoma cells by stabilization of p27kip1. Int J
Oncol. 32:377–385. 2008.PubMed/NCBI
|
|
22
|
Hoshikawa H, Indo K, Mori T and Mori N:
Enhancement of the radiation effects by D-allose in head and neck
cancer cells. Cancer Lett. 306:60–66. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Indo K, Hoshikawa H, Kamitori K, Yamaguchi
F, Mori T, Tokuda M and Mori N: Effects of D-allose in combination
with docetaxel in human head and neck cancer cells. Int J Onclol.
45:2044–2050. 2014. View Article : Google Scholar
|
|
24
|
Mitani T, Hoshikawa H, Mori T, Hosokawa T,
Tsukamoto I, Yamaguchi F, Kamitori K, Tokuda M and Mori N: Growth
inhibition of head and neck carcinomas by D-allose. Head Neck.
31:1049–1055. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kamada M, Kumazaki T, Matsuo T, Mitsui Y
and Takahashi T: Establishment of ultra long-lived cell lines by
transfection of TERT into normal human fibroblast TIG-1 and their
characterization. Cell Biol Int. 36:519–527. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Müller K and Meineke V: Radiation-induced
alterations in cytokine production by skin cells. Exp Hematol. 35 4
Suppl 1:S96–S104. 2007. View Article : Google Scholar
|
|
27
|
Metwally MA, Frederiksen KD and Overgaard
J: Compliance and toxicity of the hypoxic radiosensitizer
nimorazole in the treatment of patients with head and neck squamous
cell carcinoma (HNSCC). Acta Oncol. 53:654–661. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhai S, Senderowicz AM, Sausville EA and
Figg WD: Flavopiridol, a novel cyclin-dependent kinase inhibitor,
in clinical development. Ann Pharmacother. 36:905–911. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Goel A and Aggarwal BB: Curcumin, the
golden spice from indian saffron, is a chemosensitizer and
radiosensitizer for tumors and chemoprotector and radioprotector
for normal organs. Nutr Cancer. 62:919–930. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Butler LM, Zhou X, Xu WS, Scher HI,
Rifkind RA, Marks PA and Richon VM: The histone deacetylase
inhibitor SAHA arrests cancer cell growth, up-regulates
thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc
Natl Acad Sci USA. 99:pp. 11700–11705. 2002; View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nolan L, Johnson PW, Ganesan A, Packham G
and Crabb SJ: Will histone deacetylase inhibitors require
combination with other agents to fulfil their therapeutic
potential? Br J Cancer. 99:689–694. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shabason JE, Tofilon PJ and Camphausen K:
Grand rounds at the national institutes of health: HDAC inhibitors
as radiation modifiers, from bench to clinic. J Cell Mol Med.
15:2735–2744. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Spiegel S, Milstien S and Grant S:
Endogenous modulators and pharmacological inhibitors of histone
deacetylases in cancer therapy. Oncogene. 31:537–551. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Masoudi A, Elopre M, Amini E, Nagel ME,
Ater JL, Gopalakrishnan V and Wolff JE: Influence of valproic acid
on outcome of high-grade gliomas in children. Anticancer Res.
28:2437–2442. 2008.PubMed/NCBI
|
|
35
|
Ree AH, Dueland S, Folkvord S, Hole KH,
Seierstad T, Johansen M, Abrahamsen TW and Flatmark K: Vorinostat,
a histone deacetylase inhibitor, combined with pelvic palliative
radiotherapy for gastrointestinal carcinoma: The Pelvic Radiation
and Vorinostat (PRAVO) phase 1 study. Lancet Oncol. 11:459–464.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Candelaria M, Cetina L, Pérez-Cárdenas E,
De La Cruz-Hernández E, González-Fierro A, Trejo-Becerril C,
Taja-Chayeb L, Chanona J, Arias D and Dueñas-González A: Epigenetic
therapy and cisplatin chemoradiation in FIGO stage IIIB cervical
cancer. Eur J Gynaecol Oncol. 31:386–391. 2010.PubMed/NCBI
|
